DBT Statistics
Total Valuation
Ben Tre Pharmaceutical JSC has a market cap or net worth of VND 226.12 billion.
Market Cap | 226.12B |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Ben Tre Pharmaceutical JSC has 18.61 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 18.61M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | -0.14% |
Owned by Insiders (%) | 40.93% |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
The trailing PE ratio is 12.81.
PE Ratio | 12.81 |
Forward PE | n/a |
PS Ratio | 0.26 |
PB Ratio | 1.15 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 1.56.
Current Ratio | 1.19 |
Quick Ratio | 0.49 |
Debt / Equity | 1.56 |
Debt / EBITDA | 8.93 |
Debt / FCF | -4.71 |
Interest Coverage | 1.60 |
Financial Efficiency
Return on equity (ROE) is 8.48% and return on invested capital (ROIC) is 3.38%.
Return on Equity (ROE) | 8.48% |
Return on Assets (ROA) | 2.75% |
Return on Capital (ROIC) | 3.38% |
Revenue Per Employee | 1.46B |
Profits Per Employee | 29.85M |
Employee Count | 566 |
Asset Turnover | 1.23 |
Inventory Turnover | 2.51 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.79% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +18.79% |
50-Day Moving Average | 12,446.00 |
200-Day Moving Average | 11,656.75 |
Relative Strength Index (RSI) | 48.84 |
Average Volume (20 Days) | 7,830 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ben Tre Pharmaceutical JSC had revenue of VND 828.64 billion and earned 16.89 billion in profits. Earnings per share was 948.29.
Revenue | 828.64B |
Gross Profit | 199.81B |
Operating Income | 29.64B |
Pretax Income | 26.83B |
Net Income | 16.89B |
EBITDA | 42.66B |
EBIT | 29.64B |
Earnings Per Share (EPS) | 948.29 |
Balance Sheet
The company has 83.16 billion in cash and 380.81 billion in debt, giving a net cash position of -297.65 billion or -15,993.75 per share.
Cash & Cash Equivalents | 83.16B |
Total Debt | 380.81B |
Net Cash | -297.65B |
Net Cash Per Share | -15,993.75 |
Equity (Book Value) | 244.79B |
Book Value Per Share | 10,566.98 |
Working Capital | 93.28B |
Cash Flow
In the last 12 months, operating cash flow was -74.77 billion and capital expenditures -6.17 billion, giving a free cash flow of -80.94 billion.
Operating Cash Flow | -74.77B |
Capital Expenditures | -6.17B |
Free Cash Flow | -80.94B |
FCF Per Share | -4,348.95 |
Margins
Gross margin is 24.11%, with operating and profit margins of 3.58% and 2.04%.
Gross Margin | 24.11% |
Operating Margin | 3.58% |
Pretax Margin | 3.24% |
Profit Margin | 2.04% |
EBITDA Margin | 5.15% |
EBIT Margin | 3.58% |
FCF Margin | -9.77% |
Dividends & Yields
Ben Tre Pharmaceutical JSC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 24.72% |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 7.80% |
FCF Yield | -35.79% |
Stock Splits
The last stock split was on July 5, 2024. It was a forward split with a ratio of 1.14.
Last Split Date | Jul 5, 2024 |
Split Type | Forward |
Split Ratio | 1.14 |
Scores
Ben Tre Pharmaceutical JSC has an Altman Z-Score of 1.67. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.67 |
Piotroski F-Score | n/a |